文献速递生殖医学

新鲜囊胚移植日血清孕酮水平:活产率的关键决定因素

Serum progesterone levels on fresh blastocyst transfer day: a key determinant of live birth rates.
PubMed 文献 · Hum Reprod · 2025-01-01

这项回顾性单中心队列研究纳入2020年6月至2023年3月874例新鲜单囊胚移植患者,移植日血清孕酮46.6–72.3 ng/ml组活产率最高(38.1%),Q1、Q3、Q4组活产率均显著低于Q2组。

要点

  • 移植日血清孕酮46.6–72.3 ng/ml与最高活产率相关。
  • Q1组(10.2–46.5 ng/ml)活产率最低(21.0%),临床妊娠率也显著低于Q2组。
  • Q3和Q4组早期流产率高于Q2组,Q1组早产率高于Q2组。

核心结论

  • 新鲜囊胚移植日血清孕酮水平与活产率显著相关,46.6–72.3 ng/ml区间活产率最高。
  • 作者认为需要前瞻性研究验证该关联,并探索基于孕酮水平个体化黄体期支持的获益。

研究设计与样本

  • 回顾性单中心队列研究,纳入2020年6月至2023年3月所有单自体第5天囊胚新鲜移植周期,共874例。
  • 卵巢刺激采用标准化方案,人绒毛膜促性腺激素触发排卵,所有患者接受相同黄体期支持方案:阴道微粒化孕酮800 mg/天。
  • 移植日晨在单一实验室检测血清孕酮,临床医生对结果设盲。
  • 按血清孕酮水平四分位分组:Q1(10.2–46.5 ng/ml)、Q2(46.6–72.3 ng/ml)、Q3(72.4–106.9 ng/ml)、Q4(107.0–364.8 ng/ml)。
  • 主要结局为活产率,次要结局包括临床妊娠率、早期流产率和新生儿结局(出生体重和分娩时孕周)。

主要发现

  • 研究人群移植日血清孕酮中位数为72.3 ng/ml(范围46.5–106.9),最小10.2 ng/ml,最大364.8 ng/ml。
  • 总活产率为29.4%(260/874),Q1为21.0%,Q2为38.1%,Q3为29.5%,Q4为30.3%。
  • 多因素logistic回归显示,与Q2相比,Q1、Q3、Q4组活产率显著降低,调整OR分别为0.52(95%CI 0.32–0.82,P=0.005)、0.55(95%CI 0.36–0.86,P=0.010)、0.54(95%CI 0.34–0.85,P=0.010)。
  • Q1组临床妊娠率显著低于Q2组(29.2% vs 44.1%,P<0.001)。
  • Q3组和Q4组早期流产率分别为38.5%和35.6%,高于Q2组的12.3%(P<0.001);Q1组早产率显著高于Q2组(15.2% vs 3.6%,P=0.010)。

临床怎么用

  • 作者认为这些发现提示需要前瞻性研究验证新鲜移植周期中血清孕酮水平与妊娠结局的关联。
  • 作者提出此类研究可探索基于血清孕酮水平个体化黄体期支持的获益,包括对低孕酮病例加强孕酮补充或对高孕酮水平者采用全胚冷冻策略,以改善活产率和优化治疗结局。

局限性

  • 研究的回顾性设计是主要局限,尽管采用多因素分析试图减轻,仍可能引入选择偏倚和混杂偏倚。
  • 作者指出需要前瞻性研究验证血清孕酮水平与新鲜移植周期妊娠结局的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there an association between mid-luteal serum progesterone (P) levels on the day of fresh embryo transfer (ET) at the blastocyst stage and the live birth rate (LBR)? SUMMARY ANSWER: Serum P levels between 46.6 and 72.3 ng/ml on the day of fresh ET are associated with the highest LBR. WHAT IS KNOWN ALREADY: Luteal phase monitoring is a standard practice in frozen ET cycles to personalize luteal phase support. However, the role of serum P levels in fresh ET cycles remains underexplored and inconsistent, with some studies suggesting a link to outcomes while others show no association. STUDY DESIGN, SIZE, DURATION: This retrospective, single-center cohort study included all single autologous Day-5 blastocyst fresh ETs performed between June 2020 and March 2023. Serum P levels were measured on the day of ET. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 874 patients underwent ovarian stimulation according to standardized protocols, with ovulation triggered by human chorionic gonadotropin. All patients received the same luteal phase support regimen of vaginal micronized P (800 mg/day). Serum P levels were measured on the morning of ET in a single laboratory, with clinicians blinded to the results. Patients were divided into four quartiles based on their serum P levels: Q1 (10.2-46.5 ng/ml), Q2 (46.6-72.3 ng/ml), Q3 (72.4-106.9 ng/ml), and Q4 (107.0-364.8 ng/ml). The primary outcome was the LBR, with secondary outcomes including clinical pregnancy rates, early miscarriage rates, and neonatal outcomes (birth weight and gestational age at delivery). Univariate and multivariate logistic regression analyses were performed to identify factors associated with LBR. MAIN RESULTS AND THE ROLE OF CHANCE: The median serum P level on ET day for the entire study population was 72.3 ng/ml (range: 46.5-106.9), with a minimum value of 10.2 ng/ml and a maximum value of 364.8 ng/ml. The overall LBR was 29.4% (260/874), ranging from 21.0% in Q1 to 38.1% in Q2, 29.5% in Q3, and 30.3% in Q4. A significant association between serum P levels and LBR was observed, with Q1 showing the lowest LBR and Q2 the highest (P < 0.001). Multivariate logistic regression indicated that serum P levels in Q1, Q3, and Q4 were associated with significantly lower LBRs compared to Q2, with adjusted odds ratios of 0.52 (95% CI: 0.32-0.82, P = 0.005), 0.55 (95% CI: 0.36-0.86, P = 0.010), and 0.54 (95% CI: 0.34-0.85, P = 0.010), respectively. For secondary outcomes, clinical pregnancy rates were significantly lower in Q1 (29.2% vs 44.1%, P < 0.001). Early miscarriage rates were higher in Q3 (38.5%) and Q4 (35.6%) compared to Q2 (12.3%, P < 0.001). Preterm birth was significantly more frequent in Q1 than in Q2 (15.2% vs 3.6%, P = 0.010). LIMITATIONS, REASONS FOR CAUTION: The study's retrospective design is a key limitation, introducing potential selection and confounding biases, despite efforts to mitigate these using multivariable analysis. WIDER IMPLICATIONS OF THE FINDINGS: These findings highlight the need for prospective studies to validate the association between serum P levels and pregnancy outcomes in fresh ET cycles. Such studies could explore the benefits of personalizing luteal phase support based on serum P levels, including the potential for enhanced P supplementation in low P cases or a freeze-all approach for those with elevated P levels, to improve LBRs and optimize treatment outcomes. STUDY FUNDING/COMPETING INTEREST(S): This study received no external funding. The authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Maignien C, Fornelli G, Bourdon M, et al. Serum progesterone levels on fresh blastocyst transfer day: a key determinant of live birth rates. Hum Reprod. 2025. PMID: 40639805. doi:10.1093/humrep/deaf138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。